Armstrong Fleming & Moore’s Bristol-Myers Squibb BMY Stock Holding History

Armstrong Fleming & Moore’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$462K	Sell	8,015 -1,000	-11%	-$57.4K	0.15%	71
2026 Q1	$547K	Hold	9,015	–	–	0.23%	61
2025 Q4	$486K	Buy	9,015 +983	+12%	+$47.3K	0.22%	62
2025 Q3	$362K	Sell	8,032 -32	-0.4%	-$1.49K	0.17%	73
2025 Q2	$373K	Buy	+8,064	New	+$396K	0.2%	68
2025 Q1	–	Sell	-8,149	Closed	-$461K	–	85
2024 Q4	$461K	Hold	8,149	–	–	0.28%	60
2024 Q3	$422K	Hold	8,149	–	–	0.25%	65
2024 Q2	$338K	Hold	8,149	–	–	0.22%	67
2024 Q1	$442K	Hold	8,149	–	–	0.31%	61
2023 Q4	$418K	Hold	8,149	–	–	0.32%	62
2023 Q3	$473K	Hold	8,149	–	–	0.46%	49
2023 Q2	$521K	Buy	+8,149	New	+$546K	0.48%	47

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Armstrong Fleming & Moore's BMY Position: Q2 2026 in Review

Armstrong Fleming & Moore reduced its Bristol-Myers Squibb (BMY) stake by 11% in Q2 2026, selling an estimated $57.4K and leaving 8,015 shares worth $462K. The position accounts for 0.15% of the portfolio, ranked #71.

Armstrong Fleming & Moore first reported a position in BMY in Q2 2023 and has held it in 12 quarters since. The position peaked at $547K in Q1 2026. 2,516 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Armstrong Fleming & Moore held 8,015 shares of Bristol-Myers Squibb worth $462K as of Q2 2026.
Armstrong Fleming & Moore sold 1,000 Bristol-Myers Squibb shares in Q2 2026, an estimated $57.4K.
Bristol-Myers Squibb made up 0.15% of Armstrong Fleming & Moore's portfolio in Q2 2026, its #71 holding.
Armstrong Fleming & Moore first reported a position in Bristol-Myers Squibb in Q2 2023 and has held it in 12 quarters since.
Armstrong Fleming & Moore's Bristol-Myers Squibb position peaked at $547K in Q1 2026.
2,516 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2026, filed 28 Jul 2026.